Çava Triple Joints
Natural health product licensed in Canada
- Other names
- Çava Pharma Triple Joints, Çava Triple Joint
- Licence holder
- Çava Pharma
- NPN or DIN-HM
- 80083963
- Status
- Active licence
- Licence date
- 23 March 2018
- Revision date
- Not provided
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Bore Source : Citrate de bore | 0.5 milligramme | Not calculated |
| Calcium Source : Phosphate de calcium, dibasique | 40 milligramme | 120,000 µg |
| Méthylsulfonylméthane Source : Sulfone de diméthyl | 200 milligramme | Not calculated |
Non-medicinal ingredients
Hydroxypropylméthylcellulose, Stéarate de magnésium, Cellulose microcristalline, Glaçure pharmaceutique
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 18 years | 1 Comprimé | 3 Tous les jours |
Uses authorised in Canada
Helps to relieve joint pain associated with osteoarthritis (of the knee). Helps to protect against the deterioration of cartilage. A factor in maintaining healthy cartilage and/or joint health. Adequate calcium (and vitamin D) (throughout life) as part of a healthy diet, (along with physical activity) may help prevent bone loss/osteoporosis / may reduce the risk of developing osteoporosis (in peri- and postmenopausal women) (in later life). Helps in the development and maintenance of bones. Helps maintain healthy calcium metabolism. Bromelain is used in herbal medicine to help relieve minor pain, swelling and inflammation (anti-inflammatory).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Effets indésirables connus
Hypersensitivity (e.g. allergy) has been known to occur; in which case, discontinue use. Some people may experience mild gastrointestinal disturbances such as diarrhoea, abdominal pain, heartburn, nausea and vomiting; in which case, discontinue use.
- Précautions et mises en garde
If you are pregnant or breastfeeding, consult a health care practitioner prior to use. If symptoms worsen, consult a health care practitioner. If you have a gastrointestinal lesion/ ulcer, are taking an anticoagulant/ blood thinner, anti-inflammatory or antibiotic, or are having surgery, consult a health care practitioner prior to use. If you have been diagnosed with estrogen-dependant cancer, consult a health care practitioner prior to use. If you have a kidney disorder, consult a healthcare practitioner prior to use.
Source
Official Health Canada record, licence 80083963
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.